Lakefront Biotherapeutics, formerly Galapagos, rebranded and acquired Ouro Medicines' assets with Gilead, creating a new drug development platform. The company has €2.24 billion in liquidity to support clinical trials for gamgertamig, a drug targeting tough autoimmune diseases. While promising, gamgertamig's long-term efficacy and safety remain unproven, making future value dependent on clinical success and careful capital use. The company's current valuation reflects development risks, with upside tied to progress and avoiding costly acquisitions.
Lakefront Biotherapeutics is noted here with a focus on its €2.24 billion liquidity supporting drug development. For readers following the health sector, here is Pluang's market snapshot as of Sep 15, 2026 18:13 WIB: out of 91 priced US health stocks, 31 rose and 54 fell. Notable movers include Eli Lilly And Co (LLY) up 1.65% at USD 1,156.50, ResMed Inc. (RMD) up 1.57% at USD 226.48, and Ginkgo Bioworks Holdings Inc. (DNA) down 2.14% at USD 6.86.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
A video shared by The Bitcoin Historian quotes an unnamed wealth adviser who encourages clients to obtain one Bitcoin, believing it could increase in value by 100 times. The adviser also notes that institutional adoption and understanding of Bitcoin ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Solana recorded 8.92 billion non-vote transactions from July to September 2026, marking a 104% increase compared to the fourth quarter of 2025. These transactions exclude validator votes and include activities like transfers, trading, and decentraliz...
